Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Medicine
Published in: Clinical and Translational Medicine 1/2018

Open Access 01-12-2018 | Review

Cytokines, breast cancer stem cells (BCSCs) and chemoresistance

Authors: Weilong Chen, Yuanyuan Qin, Suling Liu

Published in: Clinical and Translational Medicine | Issue 1/2018

Login to get access

Abstract

Chemotherapy resistance of breast cancer poses a great challenge to the survival of patients. During breast cancer treatment, the development of intrinsic and acquired drug resistance tends to further induce adverse prognosis, such as metastasis. In recent years, the progress of research on cytokine-modulated tumor microenvironment and breast cancer stem cells (BCSCs) has shed light on defining the mechanisms of drug resistance gradually. In this review, we have discussed cytokine regulation on breast cancer chemoresistance. Cytokines can affect tumor cell behavior or reprogram tumor niche through specific signaling pathways, thereby regulating the progress of drug resistance. In addition, we summarized the mutually regulatory networks between cytokines and BCSCs in mediating chemoresistance. Cytokines in the tumor microenvironment can regulate the self-renewal and survival of BCSCs in a variety of ways, sequentially promoting chemotherapeutic resistance. Therefore, the combinational treatment of BCSC targeting and cytokine blockade may have a positive effect on the clinical treatment of breast cancer.
Literature
1.
2.
Tao Y, Li M, Kim B, Auguste DT (2017) Incorporating gold nanoclusters and target-directed liposomes as a synergistic amplified colorimetric sensor for HER2-positive breast cancer cell detection. Theranostics. 7(4):899–911PubMedPubMedCentralCrossRef
3.
4.
5.
Ford AM, Mansur MB, Furness CL, van Delft FW, Okamura J, Suzuki T et al (2015) Protracted dormancy of pre-leukemic stem cells. Leukemia 29(11):2202–2207PubMedPubMedCentralCrossRef
6.
7.
8.
9.
Chan CH, Morrow JK, Li CF, Gao Y, Jin G, Moten A et al (2013) Pharmacological inactivation of Skp2 SCF ubiquitin ligase restricts cancer stem cell traits and cancer progression. Cell 154(3):556–568PubMedCrossRef
10.
Cordenonsi M, Zanconato F, Azzolin L, Forcato M, Rosato A, Frasson C et al (2011) The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells. Cell 147(4):759–772PubMedCrossRef
11.
Pece S, Tosoni D, Confalonieri S, Mazzarol G, Vecchi M, Ronzoni S et al (2010) Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content. Cell 140(1):62–73PubMedCrossRef
12.
Sharma B, Varney ML, Saxena S, Wu L, Singh RK (2016) Induction of CXCR2 ligands, stem cell-like phenotype, and metastasis in chemotherapy-resistant breast cancer cells. Cancer Lett 372(2):192–200PubMedPubMedCentralCrossRef
13.
Gallego-Ortega D, Ledger A, Roden DL, Law AM, Magenau A, Kikhtyak Z et al (2015) ELF5 drives lung metastasis in luminal breast cancer through recruitment of Gr1+ CD11b+ myeloid-derived suppressor cells. PLoS Biol 13(12):e1002330PubMedPubMedCentralCrossRef
14.
15.
Wang T, Fahrmann JF, Lee H, Li YJ, Tripathi SC, Yue C et al (2018) JAK/STAT3-regulated fatty acid beta-oxidation is critical for breast cancer stem cell self-renewal and chemoresistance. Cell Metab. 27(1):136–150PubMedCrossRef
16.
Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M et al (2007) ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1(5):555–567PubMedPubMedCentralCrossRef
17.
Liu S, Cong Y, Wang D, Sun Y, Deng L, Liu Y et al (2014) Breast cancer stem cells transition between epithelial and mesenchymal states reflective of their normal counterparts. Stem Cell Rep 2(1):78–91CrossRef
18.
Tan C, Hu W, He Y, Zhang Y, Zhang G, Xu Y et al (2018) Cytokine-mediated therapeutic resistance in breast cancer. Cytokine 108:151–159PubMedCrossRef
19.
Zhao M, Liu Y, Liu R, Qi J, Hou Y, Chang J et al (2018) Upregulation of IL-11, an IL-6 family cytokine, promotes tumor progression and correlates with poor prognosis in non-small cell lung cancer. Cell Physiol Biochem 45(6):2213–2224PubMedCrossRef
20.
Koyama S, Akbay EA, Li YY, Aref AR, Skoulidis F, Herter-Sprie GS et al (2016) STK11/LKB1 deficiency promotes neutrophil recruitment and proinflammatory cytokine production to suppress T-cell activity in the lung tumor microenvironment. Cancer Res 76(5):999–1008PubMedPubMedCentralCrossRef
21.
Kulbe H, Chakravarty P, Leinster DA, Charles KA, Kwong J, Thompson RG et al (2012) A dynamic inflammatory cytokine network in the human ovarian cancer microenvironment. Cancer Res 72(1):66–75PubMedCrossRef
22.
23.
Bharti R, Dey G, Mandal M (2016) Cancer development, chemoresistance, epithelial to mesenchymal transition and stem cells: a snapshot of IL-6 mediated involvement. Cancer Lett 375(1):51–61PubMedCrossRef
24.
Cortini M, Massa A, Avnet S, Bonuccelli G, Baldini N (2016) Tumor-activated mesenchymal stromal cells promote osteosarcoma stemness and migratory potential via IL-6 secretion. PLoS ONE 11(11):e0166500PubMedPubMedCentralCrossRef
25.
He G, Dhar D, Nakagawa H, Font-Burgada J, Ogata H, Jiang Y et al (2013) Identification of liver cancer progenitors whose malignant progression depends on autocrine IL-6 signaling. Cell 155(2):384–396PubMedPubMedCentralCrossRef
26.
27.
Johnson DE, O’Keefe RA, Grandis JR (2018) Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nat Rev Clin Oncol. 15(4):234–248PubMedCrossRef
28.
Zhang X, Hu F, Li G, Li G, Yang X, Liu L et al (2018) Human colorectal cancer-derived mesenchymal stem cells promote colorectal cancer progression through IL-6/JAK2/STAT3 signaling. Cell Death Dis. 9(2):25PubMedPubMedCentralCrossRef
29.
30.
Qin X, Yan M, Wang X, Xu Q, Wang X, Zhu X et al (2018) Cancer-associated fibroblast-derived IL-6 promotes Head and neck cancer progression via the osteopontin-NF-kappa B signaling pathway. Theranostics. 8(4):921–940PubMedPubMedCentralCrossRef
31.
Li J, He K, Liu P, Xu LX (2016) Iron participated in breast cancer chemoresistance by reinforcing IL-6 paracrine loop. Biochem Biophys Res Commun 475(2):154–160PubMedCrossRef
32.
Wang K, Zhu X, Zhang K, Yin Y, Chen Y, Zhang T (2018) Interleukin-6 contributes to chemoresistance in MDA-MB-231 cells via targeting HIF-1alpha. J Biochem Mol Toxicol 32(3):e22039PubMedCrossRef
33.
Wang PC, Weng CC, Hou YS, Jian SF, Fang KT, Hou MF et al (2014) Activation of VCAM-1 and its associated molecule CD44 leads to increased malignant potential of breast cancer cells. Int J Mol Sci 15(3):3560–3579PubMedPubMedCentralCrossRef
34.
Saha S, Mukherjee S, Khan P, Kajal K, Mazumdar M, Manna A et al (2016) Aspirin suppresses the acquisition of chemoresistance in breast cancer by disrupting an NF-kappa B-IL6 signaling axis responsible for the generation of cancer stem cells. Cancer Res 76(7):2000–2012PubMedCrossRef
35.
Russo RC, Garcia CC, Teixeira MM, Amaral FA (2014) The CXCL8/IL-8 chemokine family and its receptors in inflammatory diseases. Expert Rev Clin Immunol. 10(5):593–619PubMedCrossRef
36.
Dominguez C, McCampbell KK, David JM, Palena C (2017) Neutralization of IL-8 decreases tumor PMN-MDSCs and reduces mesenchymalization of claudin-low triple-negative breast cancer. JCI Insight. 2(21):e94296PubMedCentralCrossRef
37.
Sootichote R, Thuwajit P, Singsuksawat E, Warnnissorn M, Yenchitsomanus PT, Ithimakin S et al (2018) Compound A attenuates toll-like receptor 4-mediated paclitaxel resistance in breast cancer and melanoma through suppression of IL-8. BMC Cancer. 18(1):231PubMedPubMedCentralCrossRef
38.
Jia D, Li L, Andrew S, Allan D, Li X, Lee J et al (2017) An autocrine inflammatory forward-feedback loop after chemotherapy withdrawal facilitates the repopulation of drug-resistant breast cancer cells. Cell Death Dis. 8(7):e2932PubMedPubMedCentralCrossRef
39.
40.
Meulmeester E, Ten Dijke P (2011) The dynamic roles of TGF-beta in cancer. J Pathol. 223(2):205–218PubMedCrossRef
41.
Santibanez JF, Quintanilla M, Bernabeu C (2011) TGF-beta/TGF-beta receptor system and its role in physiological and pathological conditions. Clin Sci (Lond). 121(6):233–251PubMedCrossRef
42.
Bhola NE, Balko JM, Dugger TC, Kuba MG, Sanchez V, Sanders M et al (2013) TGF-beta inhibition enhances chemotherapy action against triple-negative breast cancer. J Clin Invest. 123(3):1348–1358PubMedPubMedCentralCrossRef
43.
Zhong S, Ma T, Zhang X, Lv M, Chen L, Tang J et al (2015) MicroRNA expression profiling and bioinformatics analysis of dysregulated microRNAs in vinorelbine-resistant breast cancer cells. Gene 556(2):113–118PubMedCrossRef
44.
Karicheva O, Rodriguez-Vargas JM, Wadier N, Martin-Hernandez K, Vauchelles R, Magroun N et al (2016) PARP3 controls TGFβ and ROS driven epithelial-to-mesenchymal transition and stemness by stimulating a TG2-Snail-E-cadherin axis. Oncotarget. 7(39):64109PubMedPubMedCentralCrossRef
45.
Gulei D, Mehterov N, Ling H, Stanta G, Braicu C, Berindan-Neagoe I (2017) The, “good-cop bad-cop” TGF-beta role in breast cancer modulated by non-coding RNAs. Biochim Biophys Acta 1861(7):1661–1675PubMedCrossRef
46.
Butz H, Racz K, Hunyady L, Patocs A (2012) Crosstalk between TGF-beta signaling and the microRNA machinery. Trends Pharmacol Sci 33(7):382–393PubMedCrossRef
47.
Yu Y, Wang Y, Ren X, Tsuyada A, Li A, Liu LJ et al (2010) Context-dependent bidirectional regulation of the MutS homolog 2 by transforming growth factor beta contributes to chemoresistance in breast cancer cells. Mol Cancer Res 8(12):1633–1642PubMedPubMedCentralCrossRef
48.
49.
50.
San-Miguel J, Bladé J, Shpilberg O, Grosicki S, Maloisel F, Min C-K et al (2014) Phase 2 randomized study of bortezomib–melphalan–prednisone with or without siltuximab (anti–IL-6) in multiple myeloma. Blood 123(26):4136–4142PubMedPubMedCentralCrossRef
51.
Voorhees PM, Manges RF, Sonneveld P, Jagannath S, Somlo G, Krishnan A et al (2013) A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma. Br J Haematol. 161(3):357–366PubMedPubMedCentralCrossRef
52.
53.
54.
55.
56.
Rodón J, Carducci M, Sepulveda-Sánchez JM, Azaro A, Calvo E, Seoane J et al (2015) Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer. Invest New Drugs 33(2):357–370PubMedCrossRef
57.
58.
Brandes AA, Carpentier AF, Kesari S, Sepulveda-Sanchez JM, Wheeler HR, Chinot O et al (2016) A phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma. Neuro-oncology. 18(8):1146–1156PubMedPubMedCentralCrossRef
59.
60.
Fujiwara Y, Nokihara H, Yamada Y, Yamamoto N, Sunami K, Utsumi H et al (2015) Phase 1 study of galunisertib, a TGF-beta receptor I kinase inhibitor, in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol 76(6):1143–1152PubMedCrossRef
61.
62.
Necchi A, Giannatempo P, Mariani L, Fare E, Raggi D, Pennati M et al (2014) PF-03446962, a fully-human monoclonal antibody against transforming growth-factor β (TGFβ) receptor ALK1, in pre-treated patients with urothelial cancer: an open label, single-group, phase 2 trial. Invest New Drugs 32(3):555–560PubMedCrossRef
63.
Menacho-Marquez M, Garcia-Escudero R, Ojeda V, Abad A, Delgado P, Costa C et al (2013) The Rho exchange factors Vav2 and Vav3 favor skin tumor initiation and promotion by engaging extracellular signaling loops. PLoS Biol 11(7):e1001615PubMedPubMedCentralCrossRef
64.
Gligorijevic B, Bergman A, Condeelis J (2014) Multiparametric classification links tumor microenvironments with tumor cell phenotype. PLoS Biol 12(11):e1001995PubMedPubMedCentralCrossRef
65.
Camorani S, Hill BS, Fontanella R, Greco A, Gramanzini M, Auletta L et al (2017) Inhibition of bone marrow-derived mesenchymal stem cells homing towards triple-negative breast cancer microenvironment using an Anti-PDGFRbeta aptamer. Theranostics. 7(14):3595–3607PubMedPubMedCentralCrossRef
66.
McGranahan N, Swanton C (2017) Cancer evolution constrained by the immune microenvironment. Cell 170(5):825–827PubMedCrossRef
67.
Iida N, Dzutsev A, Stewart CA, Smith L, Bouladoux N, Weingarten RA et al (2013) Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science 342(6161):967–970PubMedCrossRef
68.
69.
Xie HY, Shao ZM, Li DQ (2017) Tumor microenvironment: driving forces and potential therapeutic targets for breast cancer metastasis. Chin J Cancer. 36(1):36PubMedPubMedCentralCrossRef
70.
Xing F, Liu Y, Sharma S, Wu K, Chan MD, Lo HW et al (2016) Activation of the c-Met pathway mobilizes an inflammatory network in the brain microenvironment to promote brain metastasis of breast cancer. Cancer Res 76(17):4970–4980PubMedPubMedCentralCrossRef
71.
Guo C, Chen Y, Gao W, Chang A, Ye Y, Shen W et al (2017) Liposomal nanoparticles carrying anti-IL6R antibody to the tumour microenvironment inhibit metastasis in two molecular subtypes of breast cancer mouse models. Theranostics. 7(3):775–788PubMedPubMedCentralCrossRef
72.
Phuengkham H, Song C, Um SH, Lim YT (2018) Implantable synthetic immune niche for spatiotemporal modulation of tumor-derived immunosuppression and systemic antitumor immunity: postoperative immunotherapy. Adv Mater. 30:1706719CrossRef
73.
Ireland L, Santos A, Campbell F, Figueiredo C, Hammond D, Ellies LG et al (2018) Blockade of insulin-like growth factors increases efficacy of paclitaxel in metastatic breast cancer. Oncogene 37(15):2022–2036PubMedPubMedCentralCrossRef
74.
Choi J, Gyamfi J, Jang H, Koo JS (2018) The role of tumor-associated macrophage in breast cancer biology. Histol Histopathol 33(2):133–145PubMed
75.
Yang C, He L, He P, Liu Y, Wang W, He Y et al (2015) Increased drug resistance in breast cancer by tumor-associated macrophages through IL-10/STAT3/bcl-2 signaling pathway. Med Oncol 32(2):352PubMedCrossRef
76.
77.
Smith NR, Baker D, Farren M, Pommier A, Swann R, Wang X et al (2013) Tumor stromal architecture can define the intrinsic tumor response to VEGF-targeted therapy. Clin Cancer Res 19(24):6943–6956PubMedCrossRef
78.
79.
Chang JT, Mani SA (2013) Sheep, wolf, or werewolf: cancer stem cells and the epithelial-to-mesenchymal transition. Cancer Lett 341(1):16–23PubMedCrossRef
80.
Zheng X, Carstens JL, Kim J, Scheible M, Kaye J, Sugimoto H et al (2015) Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. Nature 527(7579):525PubMedPubMedCentralCrossRef
81.
LeBleu VS, O’Connell JT, Gonzalez Herrera KN, Wikman H, Pantel K, Haigis MC et al (2014) PGC-1alpha mediates mitochondrial biogenesis and oxidative phosphorylation in cancer cells to promote metastasis. Nat Cell Biol. 16(10):992–1003PubMedPubMedCentralCrossRef
82.
Ozdemir BC, Pentcheva-Hoang T, Carstens JL, Zheng X, Wu CC, Simpson TR et al (2014) Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell 25(6):719–734PubMedPubMedCentralCrossRef
83.
Lee KW, Yeo SY, Sung CO, Kim SH (2015) Twist1 is a key regulator of cancer-associated fibroblasts. Cancer Res 75(1):73–85PubMedCrossRef
84.
Luo H, Tu G, Liu Z, Liu M (2015) Cancer-associated fibroblasts: a multifaceted driver of breast cancer progression. Cancer Lett 361(2):155–163PubMedCrossRef
85.
Lippitz BE (2013) Cytokine patterns in patients with cancer: a systematic review. Lancet Oncol. 14(6):e218–e228PubMedCrossRef
86.
Esquivel-Velázquez M, Ostoa-Saloma P, Palacios-Arreola MI, Nava-Castro KE, Castro JI, Morales-Montor J (2015) The role of cytokines in breast cancer development and progression. J Interf Cytok Res. 35(1):1–16CrossRef
87.
Newman G, Gonzalez-Perez RR (2014) Leptin–cytokine crosstalk in breast cancer. Mol Cell Endocrinol 382(1):570–582PubMedCrossRef
88.
Skolekova S, Matuskova M, Bohac M, Toro L, Durinikova E, Tyciakova S et al (2016) Cisplatin-induced mesenchymal stromal cells-mediated mechanism contributing to decreased antitumor effect in breast cancer cells. Cell Commun Signal. 14:4PubMedPubMedCentralCrossRef
89.
90.
Tam WL, Lu H, Buikhuisen J, Soh BS, Lim E, Reinhardt F et al (2013) Protein kinase C α is a central signaling node and therapeutic target for breast cancer stem cells. Cancer Cell 24(3):347–364PubMedPubMedCentralCrossRef
91.
Lin X, Chen W, Wei F, Zhou BP, Hung MC, Xie X (2017) Nanoparticle delivery of miR-34a eradicates long-term-cultured breast cancer stem cells via targeting C22ORF28 directly. Theranostics. 7(19):4805–4824PubMedPubMedCentralCrossRef
92.
Park EY, Chang E, Lee EJ, Lee H-W, Kang H-G, Chun K-H et al (2014) Targeting of miR34a–NOTCH1 axis reduced breast cancer stemness and chemoresistance. Cancer Res 74(24):7573–7582PubMedCrossRef
93.
Bartucci M, Dattilo R, Moriconi C, Pagliuca A, Mottolese M, Federici G et al (2015) TAZ is required for metastatic activity and chemoresistance of breast cancer stem cells. Oncogene 34(6):681–690PubMedCrossRef
94.
Samanta D, Gilkes DM, Chaturvedi P, Xiang L, Semenza GL (2014) Hypoxia-inducible factors are required for chemotherapy resistance of breast cancer stem cells. Proc Natl Acad Sci USA. 111(50):E5429–E5438PubMedCrossRef
95.
Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA. 100(7):3983–3988PubMedCrossRef
96.
Giudice FS, Pinto DS Jr, Nör JE, Squarize CH, Castilho RM (2013) Inhibition of histone deacetylase impacts cancer stem cells and induces epithelial-mesenchyme transition of head and neck cancer. PLoS ONE 8(3):e58672PubMedPubMedCentralCrossRef
97.
Kim SK, Kim H, D-h Lee, T-s Kim, Kim T, Chung C et al (2013) Reversing the intractable nature of pancreatic cancer by selectively targeting ALDH-high, therapy-resistant cancer cells. PLoS ONE 8(10):e78130PubMedPubMedCentralCrossRef
98.
99.
Nishida S, Hirohashi Y, Torigoe T, Inoue R, Kitamura H, Tanaka T et al (2013) Prostate cancer stem-like cells/cancer-initiating cells have an autocrine system of hepatocyte growth factor. Cancer Sci 104(4):431–436PubMedCrossRef
100.
Huang C-P, Tsai M-F, Chang T-H, Tang W-C, Chen S-Y, Lai H-H et al (2013) ALDH-positive lung cancer stem cells confer resistance to epidermal growth factor receptor tyrosine kinase inhibitors. Cancer Lett 328(1):144–151PubMedCrossRef
101.
Elizondo G, Medina-Diaz IM, Cruz R, Gonzalez FJ, Vega L (2009) Retinoic acid modulates retinaldehyde dehydrogenase 1 gene expression through the induction of GADD153-C/EBPbeta interaction. Biochem Pharmacol 77(2):248–257PubMedCrossRef
102.
Alvarez S, Germain P, Alvarez R, Rodriguez-Barrios F, Gronemeyer H, de Lera AR (2007) Structure, function and modulation of retinoic acid receptor beta, a tumor suppressor. Int J Biochem Cell Biol 39(7–8):1406–1415PubMedCrossRef
103.
Shima H, Yamada A, Ishikawa T, Endo I (2017) Are breast cancer stem cells the key to resolving clinical issues in breast cancer therapy? Gland Surg. 6(1):82–88PubMedPubMedCentralCrossRef
104.
W-x Chen, X-m Liu, M-m Lv, Chen L, J-h Zhao, S-l Zhong et al (2014) Exosomes from drug-resistant breast cancer cells transmit chemoresistance by a horizontal transfer of microRNAs. PLoS ONE 9(4):e95240CrossRef
105.
106.
Liu P, Kumar I, Brown S, Kannappan V, Tawari P, Tang J et al (2013) Disulfiram targets cancer stem-like cells and reverses resistance and cross-resistance in acquired paclitaxel-resistant triple-negative breast cancer cells. Br J Cancer 109(7):1876PubMedPubMedCentralCrossRef
107.
Luo M, Brooks M, Wicha MS (2015) Epithelial-mesenchymal plasticity of breast cancer stem cells: implications for metastasis and therapeutic resistance. Curr Pharm Des 21(10):1301–1310PubMedPubMedCentralCrossRef
108.
Ma X, Zhou J, Zhang C-X, Li X-Y, Li N, Ju R-J et al (2013) Modulation of drug-resistant membrane and apoptosis proteins of breast cancer stem cells by targeting berberine liposomes. Biomaterials 34(18):4452–4465PubMedCrossRef
109.
Mallini P, Lennard T, Kirby J, Meeson A (2014) Epithelial-to-mesenchymal transition: what is the impact on breast cancer stem cells and drug resistance. Cancer Treat Rev 40(3):341–348PubMedCrossRef
110.
Dethlefsen C, Hojfeldt G, Hojman P (2013) The role of intratumoral and systemic IL-6 in breast cancer. Breast Cancer Res Treat 138(3):657–664PubMedCrossRef
111.
Kim SY, Kang JW, Song X, Kim BK, Yoo YD, Kwon YT et al (2013) Role of the IL-6–JAK1–STAT3-Oct-4 pathway in the conversion of non-stem cancer cells into cancer stem-like cells. Cell Signal 25(4):961–969PubMedPubMedCentralCrossRef
112.
Ibrahim SA, Hassan H, Vilardo L, Kumar SK, Kumar AV, Kelsch R et al (2013) Syndecan-1 (CD138) modulates triple-negative breast cancer stem cell properties via regulation of LRP-6 and IL-6-mediated STAT3 signaling. PLoS ONE 8(12):e85737PubMedPubMedCentralCrossRef
113.
Lin C, Wang L, Wang H, Yang L, Guo H, Wang X (2013) Tanshinone IIA inhibits breast cancer stem cells growth in vitro and in vivo through attenuation of IL-6/STAT3/NF-κB signaling pathways. J Cell Biochem 114(9):2061–2070PubMedCrossRef
114.
Suman S, Das TP, Damodaran C (2013) Silencing NOTCH signaling causes growth arrest in both breast cancer stem cells and breast cancer cells. Br J Cancer 109(10):2587–2596PubMedPubMedCentralCrossRef
115.
Qiu M, Peng Q, Jiang I, Carroll C, Han G, Rymer I et al (2013) Specific inhibition of Notch1 signaling enhances the antitumor efficacy of chemotherapy in triple negative breast cancer through reduction of cancer stem cells. Cancer Lett 328(2):261–270PubMedCrossRef
116.
Fu Y, Chang H, Peng X, Bai Q, Yi L, Zhou Y et al (2014) Resveratrol inhibits breast cancer stem-like cells and induces autophagy via suppressing Wnt/beta-catenin signaling pathway. PLoS ONE 9(7):e102535PubMedPubMedCentralCrossRef
117.
Zhou M, Hou Y, Yang G, Zhang H, Tu G, Du YE et al (2016) LncRNA-Hh strengthen cancer stem cells generation in twist-positive breast cancer via activation of hedgehog signaling pathway. Stem Cells. 34(1):55–66PubMedCrossRef
118.
Fan P, Fan S, Wang H, Mao J, Shi Y, Ibrahim MM et al (2013) Genistein decreases the breast cancer stem-like cell population through Hedgehog pathway. Stem Cell Res Ther. 4(6):146PubMedPubMedCentralCrossRef
119.
Takebe N, Miele L, Harris PJ, Jeong W, Bando H, Kahn M et al (2015) Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update. Nat Rev Clin Oncol. 12(8):445–464PubMedPubMedCentralCrossRef
120.
Chin AR, Wang SE (2014) Cytokines driving breast cancer stemness. Mol Cell Endocrinol 382(1):598–602PubMedCrossRef
121.
Fang WB, Yao M, Brummer G, Acevedo D, Alhakamy N, Berkland C et al (2016) Targeted gene silencing of CCL2 inhibits triple negative breast cancer progression by blocking cancer stem cell renewal and M2 macrophage recruitment. Oncotarget. 7(31):49349PubMedPubMedCentral
122.
Singh JK, Simões BM, Clarke RB, Bundred NJ (2013) Targeting IL-8 signalling to inhibit breast cancer stem cell activity. Expert Opin Ther Targets. 17(11):1235–1241PubMedCrossRef
123.
Singh JK, Simões BM, Howell SJ, Farnie G, Clarke RB (2013) Recent advances reveal IL-8 signaling as a potential key to targeting breast cancer stem cells. Breast Cancer Res 15(4):210PubMedPubMedCentralCrossRef
124.
Metadata
Title
Cytokines, breast cancer stem cells (BCSCs) and chemoresistance
Authors
Weilong Chen
Yuanyuan Qin
Suling Liu
Publication date
01-12-2018
Publisher
Springer Berlin Heidelberg
Published in
Clinical and Translational Medicine / Issue 1/2018
Electronic ISSN: 2001-1326
DOI
https://doi.org/10.1186/s40169-018-0205-6

Other articles of this Issue 1/2018

Clinical and Translational Medicine 1/2018 Go to the issue

Case report

Does ALK-rearrangement predict favorable response to the therapy of bevacizumab plus pemetrexed in advanced non-small-cell lung cancer? Case report and literature review

Review

Oncolytic viruses and checkpoint inhibitors: combination therapy in clinical trials

Research

Anti-inflammatory and antiplatelet effects of non-vitamin K antagonist oral anticoagulants in acute phase of ischemic stroke patients

Case report

Bacterial biofilm formation inside colonic crypts may accelerate colorectal carcinogenesis

Review

Application of metabolomics to drug discovery and understanding the mechanisms of action of medicinal plants with anti-tuberculosis activity

Perspective

Merging perspectives: genotype-directed molecular therapy for hereditary diffuse gastric cancer (HDGC) and E-cadherin–EGFR crosstalk